Paolo L. Manfredi, MD

MGGM Therapeutics, Kerhonkson, New York

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
JCP
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
PCC
REL-1017 Effects on Cognition in MDD